{"id":"https://openalex.org/W7204720033","doi":"https://doi.org/10.1016/s2152-2650(26)00976-6","title":"POSTER: MPN-1082: Exposure-Response Analyses of Hemoglobin Changes During Epetraborole Administration to Nonhuman Primates Predict Human Exposure-Response Relationships","display_name":"POSTER: MPN-1082: Exposure-Response Analyses of Hemoglobin Changes During Epetraborole Administration to Nonhuman Primates Predict Human Exposure-Response Relationships","publication_year":2026,"publication_date":"2026-08-01","ids":{"openalex":"https://openalex.org/W7204720033","doi":"https://doi.org/10.1016/s2152-2650(26)00976-6"},"language":"en","primary_location":{"id":"doi:10.1016/s2152-2650(26)00976-6","doi":"https://doi.org/10.1016/s2152-2650(26)00976-6","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s2152-2650(26)00976-6","pdf_url":null,"source":{"id":"https://openalex.org/S186546955","display_name":"Clinical Lymphoma Myeloma & Leukemia","issn_l":"2152-2669","issn":["2152-2669","2152-2650"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Lymphoma Myeloma and Leukemia","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5037239328","display_name":"Christopher M. Rubino","orcid":"https://orcid.org/0000-0003-3172-0847","observed_orcids":["https://orcid.org/0000-0003-3172-0847"]},"institutions":[{"id":"https://openalex.org/I4210118651","display_name":"Institute for Clinical Pharmacodynamics (United States)","ror":"https://ror.org/02gck7e73","country_code":"US","type":"company","lineage":["https://openalex.org/I4210118651"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christopher M Rubino","raw_affiliation_strings":["ICPD, Schenectady, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ICPD, Schenectady, NY, USA","institution_ids":["https://openalex.org/I4210118651"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111916285","display_name":"Jeffrey Hammel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210118651","display_name":"Institute for Clinical Pharmacodynamics (United States)","ror":"https://ror.org/02gck7e73","country_code":"US","type":"company","lineage":["https://openalex.org/I4210118651"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeffrey P Hammel","raw_affiliation_strings":["ICPD, Schenectady, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ICPD, Schenectady, NY, USA","institution_ids":["https://openalex.org/I4210118651"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032245355","display_name":"Sanjay Chanda","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sanjay Chanda","raw_affiliation_strings":["AN2 Therapeutics, Inc, Menlo Park, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AN2 Therapeutics, Inc, Menlo Park, CA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5148643555","display_name":"MRK Alley","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"MRK Alley","raw_affiliation_strings":["AN2 Therapeutics, Inc, Menlo Park, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AN2 Therapeutics, Inc, Menlo Park, CA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110084290","display_name":"Alex Smith","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alex Smith","raw_affiliation_strings":["AN2 Therapeutics, Inc, Consultant, San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AN2 Therapeutics, Inc, Consultant, San Francisco, CA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080609948","display_name":"George H. Talbot","orcid":"https://orcid.org/0000-0002-2868-2707","observed_orcids":["https://orcid.org/0000-0002-2868-2707"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"George H Talbot","raw_affiliation_strings":["Talbot Advisors, Bradenton, FL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Talbot Advisors, Bradenton, FL, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5040884440","display_name":"Sujata M. Bhavnani","orcid":"https://orcid.org/0000-0003-4891-6467","observed_orcids":["https://orcid.org/0000-0003-4891-6467"]},"institutions":[{"id":"https://openalex.org/I4210118651","display_name":"Institute for Clinical Pharmacodynamics (United States)","ror":"https://ror.org/02gck7e73","country_code":"US","type":"company","lineage":["https://openalex.org/I4210118651"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sujata M Bhavnani","raw_affiliation_strings":["ICPD, Schenectady, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ICPD, Schenectady, NY, USA","institution_ids":["https://openalex.org/I4210118651"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3890,"currency":"USD","value_usd":3890},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"26","issue":null,"first_page":"S287","last_page":"S287"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T14072","display_name":"Immunotoxicology and immune responses","score":0.26440000534057617,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T14072","display_name":"Immunotoxicology and immune responses","score":0.26440000534057617,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.20890000462532043,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.03869999945163727,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/myeloproliferative-neoplasms","display_name":"myeloproliferative neoplasms","score":0.8510000109672546},{"id":"https://openalex.org/keywords/hemoglobin-change","display_name":"hemoglobin change","score":0.6700000166893005},{"id":"https://openalex.org/keywords/exposure-response-relationship","display_name":"exposure-response relationship","score":0.847000002861023},{"id":"https://openalex.org/keywords/nonhuman-primates","display_name":"non-human primates","score":0.9089999794960022},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.4230000078678131},{"id":"https://openalex.org/keywords/anemia","display_name":"anemia","score":0.3179999887943268}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9315999746322632},{"id":"https://openalex.org/C2778917026","wikidata":"https://www.wikidata.org/wiki/Q43041","display_name":"Hemoglobin","level":2,"score":0.6184999942779541},{"id":"https://openalex.org/C2780765947","wikidata":"https://www.wikidata.org/wiki/Q12033531","display_name":"Administration (probate law)","level":2,"score":0.6087999939918518},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4207000136375427},{"id":"https://openalex.org/C42407357","wikidata":"https://www.wikidata.org/wiki/Q521","display_name":"Physiology","level":1,"score":0.3982999920845032},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3384999930858612},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.289900004863739},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.28949999809265137},{"id":"https://openalex.org/C3020314195","wikidata":"https://www.wikidata.org/wiki/Q185034","display_name":"Hemoglobin s","level":4,"score":0.2540999948978424},{"id":"https://openalex.org/C2778117688","wikidata":"https://www.wikidata.org/wiki/Q264024","display_name":"Animal model","level":2,"score":0.23420000076293945}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/s2152-2650(26)00976-6","doi":"https://doi.org/10.1016/s2152-2650(26)00976-6","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s2152-2650(26)00976-6","pdf_url":null,"source":{"id":"https://openalex.org/S186546955","display_name":"Clinical Lymphoma Myeloma & Leukemia","issn_l":"2152-2669","issn":["2152-2669","2152-2650"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Lymphoma Myeloma and Leukemia","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9391000270843506}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7204729953","https://openalex.org/W7204710797","https://openalex.org/W7204732269","https://openalex.org/W2419111874","https://openalex.org/W3148337140","https://openalex.org/W7204683376","https://openalex.org/W7042419877","https://openalex.org/W7145066268","https://openalex.org/W4200538370","https://openalex.org/W2993759394"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2026-08-31T00:00:00"}